Cost-effectiveness analysis of eribulin (E) versus treatment of physician’s choice (TPC) in patients (pts) with pretreated metastatic breast cancer (MBC).
Alberto J. Montero
No relevant relationships to disclose
Kiran Kumar Venkata Raja Avancha
No relevant relationships to disclose
Stefan Gluck
No relevant relationships to disclose
Gilberto de Lima Lopes
No relevant relationships to disclose